Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Analysts are expecting strong growth driven by the robust sales of Lilly's blockbuster treatments, particularly recent launches. However, there are also concerns about potential pressures from rising